EUVIMEDEUVIMED entdecken
Crossref

The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models

Giovanni Luca Gravina, Andrea Mancini, Alessandro Colapietro, Flora Vitale, Antonella Vetuschi, Simona Pompili, Giulia Rossi, Francesco Marampon, Peter J Richardson, Lee Patient, Lee Patient, Stephen Burbidge und 1 weitere

Tumor Biology · 2017-06 · 39 (6) · 101042831769552

DOI: 10.1177/1010428317695528 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Tumor Biology, online erschienen am 22.06.2017. Verfasst von Giovanni Luca Gravina und 12 weiteren Autor:innen. Beteiligte Einrichtung: 1 Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, L'Aquila, Italy. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 52 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma is the most frequent and the most lethal primary brain tumor among adults. Standard of care is the association of radiotherapy with concomitant or adjuvant temozolomide. However, to date, recurrence is inevitable. The CXCL12/CXCR4 pathway is upregulated in the glioblastoma tumor microenvironment regulating tumor cell proliferation, local invasion, angiogenesis, and the efficacy of radio-chemotherapy. In this study, we evaluated the effects of the novel CXCR4 antagonist, PRX177561, in preclinical models of glioblastoma. CXCR4 expression and PRX177561 effects were assessed on a panel of 12 human glioblastoma cells lines and 5 patient-derived glioblastoma stem cell cultures. Next, the effect of PRX177561 was tested in vivo, using subcutaneous injection of U87MG, U251, and T98G cells as well as orthotopic intrabrain inoculation of luciferase-transfected U87MG cells. Here we found that PRX177561 impairs the proliferation of human glioblastoma cell lines, increases apoptosis, and reduces CXCR4 expression and cell migration in response to stromal cell-derived factor 1alpha in vitro. PRX177561 reduced the expression of stem cell markers and increased that of E-cadherin and glial fibrillary acidic protein in U87MG cells consistent with a reduction in cancer stem cells. In vivo, PRX177561 reduced the weight and increased the time to progression of glioblastoma subcutaneous tumors while increasing disease-free survival and overall survival of mice bearing orthotopic tumors. Our findings suggest that targeting stromal cell-derived factor 1 alpha/CXCR4 axis by PRX177561 might represent a novel therapeutic approach against glioblastoma and support further investigation of this compound in more complex preclinical settings in order to determine its therapeutic potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdultAnimalsCell DifferentiationCell Line, TumorCell MovementCell ProliferationChemokine CXCL12Disease-Free SurvivalGlioblastomaHumansMiceNeoplasm Recurrence, LocalNeoplastic Stem CellsNeovascularization, PathologicReceptors, CXCR4Signal TransductionTumor Microenvironment

Stichwörter der Autor:innen

CXCR4Glioblastomaangiogenesismonocyte infiltration

Substanzen

CXCR4 protein, humanChemokine CXCL12Receptors, CXCR4

Autor:innen und Institutionen

  • 1 Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, L'Aquila, Italy.
  • 2 Department of Biotechnological and Applied Clinical Sciences, Division of Radiotherapy, University of L'Aquila, L'Aquila, Italy.
  • 3 Department of Biotechnological and Applied Clinical Sciences, Neurobiology Laboratory, University of L'Aquila, L'Aquila, Italy.
  • 4 Department of Biotechnological and Applied Clinical Sciences, Laboratory of Human Anatomy, University of L'Aquila, L'Aquila, Italy.
  • 5 Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
  • 6 Proximagen Ltd., Cambridge, UK.

Zitieren

APA

Gravina, G. L., Mancini, A., Colapietro, A., Vitale, F., Vetuschi, A., Pompili, S., Rossi, G., Marampon, F., Richardson, P. J., Patient, L., Patient, L., Burbidge, S., & Festuccia, C. (2017). The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models. Tumor Biology, 39(6), 101042831769552. https://doi.org/10.1177/1010428317695528

Vancouver

Gravina GL, Mancini A, Colapietro A, Vitale F, Vetuschi A, Pompili S, et al. The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models. Tumor Biology. 2017;39(6):101042831769552. doi:10.1177/1010428317695528

BibTeX
@article{Gravina2017,
  author = {Gravina, Giovanni Luca and Mancini, Andrea and Colapietro, Alessandro and Vitale, Flora and Vetuschi, Antonella and Pompili, Simona and Rossi, Giulia and Marampon, Francesco and Richardson, Peter J and Patient, Lee and Patient, Lee and Burbidge, Stephen and Festuccia, Claudio},
  title = {The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models},
  journal = {Tumor Biology},
  year = {2017},
  volume = {39},
  number = {6},
  pages = {101042831769552},
  doi = {10.1177/1010428317695528}
}
Kostenlos starten →